Related Experiment Video

Updated: Jul 9, 2026

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
12:03

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy

Published on: September 5, 2016

Anti-HIV cellular immunotherapy in AIDS

D Zagury

    Lancet (London, England)
    |September 14, 1991
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies
    07:10

    Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies

    Published on: January 7, 2019

    Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection
    08:15

    Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection

    Published on: January 31, 2020

    Related Experiment Videos

    Last Updated: Jul 9, 2026

    Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
    12:03

    Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy

    Published on: September 5, 2016

    Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies
    07:10

    Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies

    Published on: January 7, 2019

    Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection
    08:15

    Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection

    Published on: January 31, 2020

    Related Concept Videos

    Retrovirus Life Cycles01:10

    Retrovirus Life Cycles

    Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
    Antiviral Nucleoside Inhibitors01:22

    Antiviral Nucleoside Inhibitors

    Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...

    Articles linked to this work by shared authors, journal, and citation graph.

    Early and long-lasting protection from arthritis in tumour necrosis factor alpha (TNFalpha) transgenic mice vaccinated against TNFalpha.

    Annals of the rheumatic diseases·2007

    Non-toxic immunogens for therapeutic anticytokine vaccines.

    IDrugs : the investigational drugs journal·2005

    Therapeutic vaccine to control stromal tumor-induced immunosuppression in human uterine cervixc cancer.

    Cellular and molecular biology (Noisy-le-Grand, France)·2003

    Active versus passive anti-cytokine antibody therapy against cytokine-associated chronic diseases.

    Cytokine & growth factor reviews·2003

    Targeting Tat and IFN(alpha) as a therapeutic AIDS vaccine.

    DNA and cell biology·2002

    Selective activation of cervical microvascular endothelial cells by human papillomavirus 16-e7 oncoprotein.

    Journal of the National Cancer Institute·2001

    1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

    Lancet (London, England)·2026

    Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

    Lancet (London, England)·2026

    Advancing the relevance of clinical trials for older patients.

    Lancet (London, England)·2026

    Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

    Lancet (London, England)·2026

    Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

    Lancet (London, England)·2026

    Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

    Lancet (London, England)·2026

    Correction: An integrated automated deep learning framework for annotating tumor-infiltrating lymphocytes in lung adenocarcinoma pathology.

    Frontiers in bioinformatics·2026

    Development and pilot validation of a chemiluminescence immunoassay for monitoring immunologic changes during peanut oral immunotherapy using sIgE/sIgG4 ratio.

    Frontiers in allergy·2026

    Real-world outcomes of subcutaneous infliximab in a Middle Eastern inflammatory bowel disease cohort: a prospective study of switch and de novo treatment strategies.

    Crohn's & colitis 360·2026

    A pipeline for cell migration analysis in live-cell imaging data from human iPSC-derived forebrain assembloids.

    Frontiers in cell and developmental biology·2026

    Tislelizumab-induced myositis antibody-negative myasthenia gravis in patients with urothelial carcinoma: a case report.

    Frontiers in immunology·2026

    Case Report: Localized neutrophilic dermatosis at a split-skin donor site during PD-1 blockade: a unique immune-related adverse event.

    Frontiers in immunology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us